NanoViricides, Inc. (NYSE: NNVC) raises ~$3.8M in direct offering with warrants
Rhea-AI Filing Summary
NanoViricides, Inc. entered into a securities purchase agreement with a single investor for a registered direct offering, selling 2,416,339 shares of common stock at $1.53 per share and pre-funded warrants for 100,000 shares at $1.52999, together with common warrants to purchase 2,516,339 shares at an exercise price of $1.75.
The pre-funded warrants are immediately exercisable at $0.00001 per share, while the common warrants become exercisable six months after issuance and expire five and one-half years from that date. The offering closed on July 27, 2026, generating approximately $3.8 million in gross proceeds before fees, to be used for working capital, capital expenditures, research and development, clinical trials, and potential acquisitions and other strategic purposes. The company agreed to a 60-day restriction on additional equity issuances (with limited exceptions), 30-day lock-ups for its chief executive officer and principal stockholder, and to file a resale registration for warrant shares within 30 days of closing, while paying a 7.0% placement fee and up to $50,000 of placement agent expenses.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Common shares sold: 2,416,339 shares
Pre-funded warrant shares: 100,000 shares
Common warrant coverage: 2,516,339 shares
+7 more
10 metrics
Common shares sold
2,416,339 shares
Shares of common stock sold at $1.53 per share in the registered direct offering
Pre-funded warrant shares
100,000 shares
Underlying shares purchasable via pre-funded warrants offered at $1.52999 each, exercise price $0.00001
Common warrant coverage
2,516,339 shares
Shares of common stock underlying common warrants exercisable at $1.75, expiring five and one-half years from issuance
Gross offering proceeds
$3.8 million
Approximate aggregate gross proceeds before placement agent fees and offering expenses
Common share offering price
$1.53 per share
Price per share of common stock sold in the registered direct offering
Common warrant exercise price
$1.75 per share
Exercise price for each share underlying the common warrants issued in the transaction
Placement fee rate
7.0%
Cash fee on aggregate gross proceeds payable to the placement agent
Placement expense reimbursement cap
$50,000
Maximum amount of the placement agent’s fees and expenses reimbursable by the company
Company issuance lock-up
60 days
Period after closing when the company agreed not to issue most new equity or equivalents
Insider lock-up period
30 days
Duration CEO and principal stockholder agreed to restrict transfers of their securities after closing
Key Terms
registered direct offering, pre-funded warrants, Common Warrants, shelf registration statement, +2 more
6 terms
registered direct offering financial
"agreed to sell and issue to the Investor in a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
pre-funded warrants financial
"pre-funded warrants to purchase up to 100,000 shares of Common Stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Common Warrants financial
"accompanying common warrants to purchase up to 2,516,339 shares of Common Stock"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
shelf registration statement regulatory
"made pursuant to an effective shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
lock-up agreements financial
"entered into lock-up agreements which prohibits them from offering for sale"
A lock-up agreement is a contract that prevents company insiders—founders, employees, and early investors—from selling their shares for a set period after a public stock offering. It matters to investors because it keeps a large block of shares off the market temporarily; when the lock-up ends, those holders can sell and this increased supply can cause the stock price to fall, similar to a timed release that suddenly opens a valve.
Orphan Drug Designation medical
"NV-387 has been granted an “Orphan Drug Designation” by the US FDA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What financing transaction did NanoViricides (NNVC) complete in July 2026?
NanoViricides completed a registered direct offering with a single investor, selling 2,416,339 common shares at $1.53, issuing pre-funded warrants for 100,000 shares, and common warrants for 2,516,339 shares at $1.75, for gross proceeds of about $3.8 million.
What are the exercise terms of the new NanoViricides (NNVC) warrants?
Each pre-funded warrant is immediately exercisable for one share at an exercise price of $0.00001 and remains exercisable until used. Each common warrant is exercisable into one share at $1.75, becomes exercisable six months after issuance, and expires five and one-half years from issuance.
How will NanoViricides (NNVC) use the approximately $3.8 million in gross proceeds?
The company plans to use the roughly $3.8 million in gross proceeds for working capital, capital expenditures, research and development, clinical trial expenditures, and for acquisitions and other strategic purposes, after deducting placement agent fees and offering expenses.
What lock-up and issuance restrictions accompany the NanoViricides (NNVC) offering?
NanoViricides agreed for 60 days after closing not to issue or agree to issue most new equity or equivalents, with limited exceptions. Its CEO and principal stockholder also signed lock-up agreements restricting sales or transfers of their securities for 30 days after closing.
When did the NanoViricides (NNVC) registered direct offering close and under what registration?
The offering closed on July 27, 2026. The securities were issued under an effective Form S-3 shelf registration statement, with a related prospectus supplement filed describing the specific terms of this registered direct offering.
What is NanoViricides (NNVC) clinical asset NV-387 mentioned in the disclosure?
NV-387 is described as a clinical-stage broad-spectrum antiviral that has received Orphan Drug Designation from the US FDA Office of Orphan Products Development, potentially providing 7 years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval.